Saturday 17 October 2026
Export NSPR’s income statement to Excel — free account
InspireMD, Inc.
NSPR Healthcare Medical Devices
InspireMD, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $9.0 million, up 28.1% from fiscal 2024. In the quarter to June 2026, revenue was flat, EPS grew 34.6% and free cash flow fell 26.0%, each against the same quarter a year earlier. Revenue growth for five consecutive years; insiders bought in the last twelve months.
0.46
0.02
−4.17%
Follow NSPR
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
22.76 | 12.75 | 12.59 | 5.47 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(20.51) | (12.25) | (11.07) | (5.44) | |
P/B ratio |
2.76 | 2.07 | 3.13 | 1.88 | |
Price to Tangible BV |
2.76 | 2.08 | 3.13 | 1.88 | |
EV/Sales |
15.10 | 7.14 | 9.11 | 3.01 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(3.61) | (1.83) | (2.56) | (0.79) | |
EV/FCF |
(3.45) | (1.74) | (2.46) | (0.77) | |
Quick Ratio |
6.09 | 5.30 | 4.70 | 3.40 | |
Current Ratio |
6.51 | 5.74 | 5.15 | 3.80 | |
Net Debt/EBITDA |
4.91 | 4.54 | 3.01 | 2.13 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.12 | 0.15 | 0.23 | 0.28 | |
Operating CF/Net income |
0.68 | 0.79 | 0.90 | 0.76 | |
Capex/Depreciation |
(2.45) | (2.78) | (1.30) | (2.09) | |
Research and Development Expense of Revenue |
144.07% | 110.35% | 140.17% | 242.52% | |
Selling, General and Administrative Expense of Revenue |
407.45% | 310.86% | 291.41% | 529.42% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
140.47% | 90.44% | 61.95% | 125.24% | |
Graham Net Nets |
0.32 | 0.41 | 0.26 | 0.40 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(34.85%) | (44.38%) | (44.79%) | (91.43%) | |
Free Cash Flow Yield |
(19.24%) | (32.10%) | (29.38%) | (71.62%) | |
Revenue per Share |
0.03 | 0.05 | 0.04 | 0.02 | |
Operating CF per Share |
(0.12) | (0.15) | (0.15) | (0.13) | |
Capex per Share |
0.00 | (0.01) | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.12) | (0.15) | (0.15) | (0.13) | |
Cash per Share |
0.86 | 0.84 | 0.50 | 0.36 | |
Shareholders Equity per Share |
0.87 | 0.86 | 0.52 | 0.37 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.87 | 0.86 | 0.52 | 0.37 | |
Free Cash Flow |
(8.95) | (9.74) | (12.53) | (11.22) | |
Working Capital |
59.58 | 50.76 | 39.15 | 26.98 | |
Capital Expenditures |
(0.31) | (0.40) | (0.19) | (0.33) | |
Net Current Asset Value |
56.03 | 47.27 | 35.74 | 23.50 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.12 | 0.13 | 0.06 | 0.19 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
2.35 | 2.41 | 2.57 | 2.25 | |
Average Payables |
9.04 | 9.20 | 8.41 | 9.36 | |
Average Inventory |
3.03 | 2.98 | 2.93 | 2.88 | |
Average Assets |
64.48 | 58.11 | 47.57 | 38.99 | |
Average Common Equity |
52.73 | 45.64 | 35.98 | 25.88 |
Columns are period end dates